We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urinary Biomarker Found for Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 Nov 2010
A protein in urine could be a reliable marker for prostate cancer assessment and has advantages over the standard prostate specific antigen (PSA) test. More...


The protein, microseminoprotein-beta (MSMB), which is produced by normal prostate cells and secreted into urine from semen, regulates cell apoptosis or programmed cell death and is linked to an increased risk of developing prostate cancer.

In a multi-institute collaborative study, led by scientists from the Institute of Cancer Research, (CRUK; Cambridge, UK), tissue, urine and blood samples were analyzed from cohorts of prostate cancer patients. Urinary PSA and MSMB levels were determined by enzyme-linked immunoassays (ELISA) and normalized to creatinine. Samples from 133 of the patients were made into a tissue microarrays (TMA) containing multiple cores from normal/benign regions (>3), prostatic intraepithelial neoplasia (PIN) and at least two distinct regions of tumor for each patient. Genotyping was performed on DNA extracted from blood samples.

The urinary levels of MSMB were determined in 215 men with no history of prostate disease and 89 men with prostate cancer. Consistent with the association in prostate tissue there was a significant decrease in urinary MSMB in men with tumors compared with men with no history of prostate disease. No normal or tumorigenic tissues demonstrated any MSMB staining suggesting that at the protein level in tissue MSMB is highly prostate specific. In particular the tissues surrounding the prostate, such as urothelium, seminal vesicles and bladder muscularis propria layer showed no staining whereas adjacent benign prostate glands were heavily stained. MSMB demonstrated high levels of specificity and sensitivity particularly when compared to urinary PSA. There was a significant decrease in urinary MSMB with the high risk allele compared to the low risk allele.

Hayley Whitaker, Ph.D., the lead author, said, "Microseminoprotein-beta (MSMB), is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk". The study was published on line on October 13, 2010, in the open access journal from the Public Library of Science, PLoS One.

Related Links:
Institute of Cancer Research



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
ESR Analyzer
TEST1 2.0
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.